In 2024, Modern Retina covered news from around the globe on clinical trials, technology in retina, trending topics in ...

Panelists discuss how anti-VEGF therapies have dramatically improved visual outcomes in patients with age-related macular degeneration and diabetic macular edema over the past decade. Key challenges ...

Panelists discuss how aflibercept’s molecular structure contributes to its clinical efficacy as a standard treatment for retinal vascular diseases.

The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) announced opinions for three biosimilar candidates from Celltrion, including a biosimilar for reference ...

Espansione Group is known for photobiomodulation (PBM) technology – the Light Modulation Low-level Light Therapy (LLLT) along with the Intense Pulsed Light (IPL) technology. EssilorLuxottica has ...

In the statement, the board calls attention to a proposal by a committee in the US House of Representatives that would shrink the National Institutes of Health’s (NIH) from 27 institutes into 15 ...

In the LIGHTHOUSE study, Atsena Therapeutics is evaluating ATSN-201 gene therapy for X-linked retinoschisis, leveraging AAV.SPR capsid for central retina transduction without foveal detachment risks.